SARS-CoV-2 Spike P681H Antibody [1G8D11] (Alpha, Mu Variant)

Infectious Disease, COVID-19

Anti-SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike P681H antibody (PM-9373) was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 Alpha variant (B.1.1.7) Spike protein.

The immunogen is located within 650-700 amino acids of SARS-CoV-2 Alpha Variant (B.1.1.7, UK) Spike protein.

May cross-react with several virus of interest (VOI) variant lineages that contains P681H mutation, including B.11.318, B.1.621, B.1.621.1, P.3. But all of these lineages are rarely present in current pandemic.

Monoclonal

IgG2a, Kappa

SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

S

1791269090

Optimal dilutions for each application to be determined by the researcher.

surface glycoprotein

In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7 and named as Alpha variant, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of alpha variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in apha variant. Alpha variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H mutation in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.

Gu et al. Science 369(6511):1603-1607

Davies et al. Science 372(6538):eabg3055.

Graham, et al. The Lancet Public Health. 6(5): e335-e345.

Figure 1 ELISA Validation of P681H Mutant Specific Spike Antibodies with Spike S1 Protein of SARS-CoV-2 Variants
Coating Antigen: SARS-CoV-2 spike S1 proteins, including WT, alpha variant (B.1.1.7, UK), beta variant (B.1.351, SA), gamma variant (P.1, Brazil), and delta variant (B.1.617.2, India), 1 μ g/mL, incubate at 4 ˚ C overnight.Detection Antibodies: SARS-CoV-2 P681H Mutant Specific Spike antibody, PM-9373, dilution: 200-1000 ng/mL, incubate at RT for 1 hr.Secondary Antibodies: Goat anti-mouse HRP at 1:5, 000, incubate at RT for 1 hr.SARS-CoV-2 P681H Mutant Specific Spikee antibody (PM-9373) can specifically detect alpha variant spike S1 protein, but not spike S1 protein of WT and other tested variants by ELISA.

Figure 3 WB Validation of P681H Mutant Specific Spike Antibodies with SARS-CoV-2 Alpha Variant Spike S1 Protein
Loading: 50 ng of SARS-CoV-2 spike S1 proteins, including WT and alpha variant (B.1.1.7, UK).Detection Antibodies: SARS-CoV-2 P681H Mutant Specific Spike antibody, PM-9373, 1 μ g/mL, incubate at RT for 1 hr.Secondary Antibodies: Goat anti-mouse HRP at 1:5, 000, incubate at RT for 1 hr.SARS-CoV-2 P681H Mutant Specific Spike antibody (PM-9373) can specifically detect alpha variant spike S1 protein, but not WT spike S1 protein (10-300) by WB.